MYDA Advisors’s Protagonist Therapeutics PTGX Stock Holding History

MYDA Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12,000	Closed	-$1.05M	–	195
2025 Q4	$1.05M	Buy	+12,000	New	+$982K	0.2%	83

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

MYDA Advisors's PTGX Position: Q4 2024 in Review

MYDA Advisors sold out of Protagonist Therapeutics (PTGX) in Q4 2024, closing a stake of 10,000 shares — an estimated $450K sold.

MYDA Advisors first reported a position in PTGX in Q3 2024 and held it in 1 quarter. The position peaked at $450K in Q3 2024. 241 funds tracked by Wall St. Rank hold PTGX as of Q4 2024.

MYDA Advisors reported no remaining Protagonist Therapeutics position as of Q4 2024 after selling out during the quarter.
MYDA Advisors sold 10,000 Protagonist Therapeutics shares in Q4 2024, an estimated $450K.
MYDA Advisors first reported a position in Protagonist Therapeutics in Q3 2024 and held it in 1 quarter.
MYDA Advisors's Protagonist Therapeutics position peaked at $450K in Q3 2024.
241 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2024.

Based on MYDA Advisors's 13F filing for Q4 2024, filed 13 Feb 2025.